Is SABR the best way to radiate the prostate??!
Stereotactic Ablative Body Radiotherapy (SABR) has been a great tool for managing low volume metastatic prostate cancer for a few years now. One or two visits to the radiation centre, highly targeted, minimal side-effects. So could it be used to treat the primary prostate cancer itself with similar success? Today we have top SABR experts Dr Alison Tree (Royal Marsden Hospital, London), and Associate Professor Shankar SIva (Peter Mac, Melbourne) in the GU Cast studio, and Dr Gerard Morton on Zoom from Sunnybrook Cancer Centre in Toronto. Alison talks through the most recent update from the PACE-B study and we ask which technology is best for prostate cancer. Also available as a classic audio podcast in all the usual places https://www.buzzsprout.com/904063/130...
Ep. 22 - Is SBRT (Cyberknife) a Good Treatment for Prostate Cancer?
Radiation therapy for prostate cancer: the basics
4 Extension Exercises That May Help a Herniated Disc
Gleason Score 8 vs Lower Scores | What's The Real Difference?
Surgery or Radiotherapy for Prostate Cancer? Here's What the Evidence Shows
Stereotactic Body Radiotherapy for Prostate Cancer | Amar Kishan, MD | UCLAMDChat
I Completed Radiation for Prostate Cancer Radiation Recurrence, and Now I Get My Mojo Back
Active Surveillance for Low Risk Prostate Cancer by Lawrence Klotz
Stop Blind Biopsies: Near-Perfect Prostate Cancer Accuracy with Dr. Mark Emberton - EP 170
SRS/SBRT - Prostate, Pancreas & Liver - By M Matuszak Ph.D & M Feng, M.D.
SBRT & CyberKnife: Who Can Skip ADT/Lupron in Prostate Cancer? with Dr. Jonathan Haas | EP 134
The Complete Guide to SBRT for Prostate Cancer | Amar Kishan, MD, UCLA
Understanding Radiation Therapy for Prostate Cancer
Most Men with Prostate Cancer are Choosing This Instead
Radical prostatectomy vs radiation therapy
Surviving Prostate Cancer: How To Prepare For Radiation Therapy After It Returns
ADT for Prostate Cancer: Agonists vs Antagonists
2025 Radiation & Side Effects For #ProstateCancer | Amar Kishan, MD & Q+A with Mark Moyad, MD #PCRI
Long Term Outcomes of HDR
